Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Drug Profile

Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Alternative Names: Aerosolised amikacin; Amikacin inhale; BAY-416551; Inhaled amikacin; NKTR-061

Latest Information Update: 25 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Bayer HealthCare; Nektar Therapeutics
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections; Nosocomial pneumonia

Most Recent Events

  • 13 Jan 2018 Bayer terminates its licence for inhaled amikacin
  • 07 Apr 2017 Bayer completes the phase III INHALE 2 trial in Gram-negative infections and Nosocomial pneumonia in Belgium, China, France, Germany, Greece, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Portugal, Russia, Spain, Ukraine, Czech Republic, Latvia (NCT00805168)
  • 06 Apr 2017 Bayer completes the phase III INHALE 1 trial in Gram-negative infections and Nosocomial pneumonia in USA, Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, South Korea, Mexico, Philippines, Taiwan, Thailand, Turkey (NCT01799993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top